The invention relates to compounds of general formula (I); 1a, 1 b, 1 c and 1 d. The invention also relates to a method for the production thereof, pharmaceutical preparations containing said compounds and/or physiologically compatible salts thereof which can be produced therefrom and/or solvates thereof, and to the pharmaceutical use of said compounds, salts or solvates thereof as inhibitors of phosphodiesterase 4. The compounds comprise active ingredients for the treatment of diseases which can have a positive influence by inhibiting the activity of phosphodiesterase 4 and/or TNFα-release, for example, in lymphocytes, eosinophile and basophile granulocytes, macrophages and mastocytes.
本发明涉及通式(I)的化合物,其中包括1a、1b、1c和1d。本发明还涉及其生产方法,包含所述化合物和/或可由其制备的生理兼容盐和/或溶剂化物的药物制剂,以及所述化合物、盐或溶剂化物作为
磷酸二酯酶4的
抑制剂的药物用途。这些化合物包含治疗疾病的活性成分,通过抑制
磷酸二酯酶4和/或TNFα释放的活性,例如在淋巴细胞、嗜酸性粒细胞和嗜碱性粒细胞、巨噬细胞和肥大细胞中产生正面影响。